Angion Biomedica Corp. ANGN
We take great care to ensure that the data presented and summarized in this overview for Angion Biomedica Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ANGN
Top Purchases
Top Sells
About ANGN
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
Insider Transactions at ANGN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Peter De Muth Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
381
+50.0%
|
$1,524
$4.41 P/Share
|
|
Nov 26
2024
|
Jay Venkatesan Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
50,000
+21.78%
|
$0
$0.01 P/Share
|
|
Dec 22
2023
|
Yekaterina Chudnovsky Director |
BUY
Open market or private purchase
|
Indirect |
1,213,000
+38.77%
|
$6,065,000
$5.81 P/Share
|
|
Jul 01
2022
|
Itzhak Goldberg Director |
SELL
Payment of exercise price or tax liability
|
Direct |
32,082
-1.87%
|
$32,082
$1.12 P/Share
|
|
May 25
2022
|
Jay Venkatesan Director |
BUY
Open market or private purchase
|
Direct |
11,313
+0.59%
|
$11,313
$1.25 P/Share
|
|
May 24
2022
|
Jay Venkatesan Director |
BUY
Open market or private purchase
|
Direct |
32,200
+1.84%
|
$32,200
$1.24 P/Share
|
|
May 20
2022
|
Jay Venkatesan Director |
BUY
Open market or private purchase
|
Direct |
50,000
+2.87%
|
$50,000
$1.23 P/Share
|
|
May 20
2022
|
Allen Nissenson Director |
BUY
Open market or private purchase
|
Direct |
2,037
+17.84%
|
$2,037
$1.18 P/Share
|
|
May 19
2022
|
Allen Nissenson Director |
BUY
Open market or private purchase
|
Direct |
7,346
+50.0%
|
$7,346
$1.16 P/Share
|
|
Dec 28
2021
|
Jay Venkatesan Director |
BUY
Open market or private purchase
|
Direct |
210,337
+11.37%
|
$420,674
$2.66 P/Share
|
|
Dec 27
2021
|
Jay Venkatesan Director |
BUY
Open market or private purchase
|
Direct |
66,907
+4.47%
|
$133,814
$2.55 P/Share
|
|
Dec 20
2021
|
Jay Venkatesan Director |
BUY
Open market or private purchase
|
Direct |
3,527
+0.26%
|
$7,054
$2.54 P/Share
|
|
Dec 20
2021
|
John F. Neylan Officer |
SELL
Open market or private sale
|
Direct |
358
-1.01%
|
$716
$2.62 P/Share
|
|
Dec 17
2021
|
Jay Venkatesan Director |
BUY
Open market or private purchase
|
Direct |
13,742
+1.0%
|
$27,484
$2.54 P/Share
|
|
Dec 16
2021
|
Jay Venkatesan Director |
BUY
Open market or private purchase
|
Direct |
27,883
+2.03%
|
$55,766
$2.55 P/Share
|
|
Dec 15
2021
|
Jay Venkatesan Director |
BUY
Open market or private purchase
|
Direct |
77,604
+5.57%
|
$155,208
$2.41 P/Share
|
|
Dec 15
2021
|
Gregory S Curhan Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+50.0%
|
$8,000
$2.37 P/Share
|
|
Dec 14
2021
|
Jennifer J Rhodes Officer |
SELL
Open market or private sale
|
Direct |
451
-1.46%
|
$902
$2.42 P/Share
|
|
Dec 06
2021
|
Itzhak Goldberg Director |
SELL
Open market or private sale
|
Direct |
32,118
-1.83%
|
$96,354
$3.35 P/Share
|
|
Dec 03
2021
|
Itzhak Goldberg Director |
SELL
Open market or private sale
|
Direct |
40,215
-2.24%
|
$120,645
$3.39 P/Share
|
Last 12 Months Summary
| Exercise of in-the-money or at-the-money derivatives securities | 50K shares |
|---|---|
| Exercise of conversion of derivative security | 381 shares |